|
1
|
Ledermann JA and Kristeleit RS: Optimal
treatment for relapsing ovarian cancer. Ann Oncol. 21(Suppl 7):
vii218–vii222. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schorge JO, Modesitt SC, Coleman RL, Cohn
DE, Kauff ND, Duska LR and Herzog TJ: SGO White Paper on ovarian
cancer: Etiology, screening and surveillance. Gynecol Oncol.
119:7–17. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Parmar MK, Ledermann JA, Colombo N, du
Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W,
Torri V, et al ICON AGO Collaborators: Paclitaxel plus
platinum-based chemotherapy versus conventional platinum-based
chemotherapy in women with relapsed ovarian cancer: The
ICON4/AGO-OVAR-2.2 trial. Lancet. 361:2099–2106. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bookman MA: The addition of new drugs to
standard therapy in the first-line treatment of ovarian cancer. Ann
Oncol. 21(Suppl 7): vii211–vii217. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shirahata A, Shinmura K, Kitamura Y,
Sakuraba K, Yokomizo K, Goto T, Mizukami H, Saito M, Ishibashi K,
Kigawa G, et al: MACC1 as a marker for advanced colorectal
carcinoma. Anticancer Res. 30:2689–2692. 2010.PubMed/NCBI
|
|
7
|
Shirahata A, Sakata M, Kitamura Y,
Sakuraba K, Yokomizo K, Goto T, Mizukami H, Saito M, Ishibashi K,
Kigawa G, et al: MACC 1 as a marker for peritoneal-disseminated
gastric carcinoma. Anticancer Res. 30:3441–3444. 2010.PubMed/NCBI
|
|
8
|
Shimokawa H, Uramoto H, Onitsuka T,
Chundong G, Hanagiri T, Oyama T and Yasumoto K: Overexpression of
MACC1 mRNA in lung adenocarcinoma is associated with postoperative
recurrence. J Thorac Cardiovasc Surg. 141:895–898. 2011. View Article : Google Scholar
|
|
9
|
Shirahata A, Fan W, Sakuraba K, Yokomizo
K, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H, et
al: MACC 1 as a marker for vascular invasive hepatocellular
carcinoma. Anticancer Res. 31:777–780. 2011.PubMed/NCBI
|
|
10
|
Zhang RT, Shi HR, Huang HL, Chen ZM, Liu
HN and Yuan ZF: Expressions of MACC1, HGF, and C-met protein in
epithelial ovarian cancer and their significance. Nan Fang Yi Ke Da
Xue Xue Bao. 31:1551–1555. 2011.In Chinese. PubMed/NCBI
|
|
11
|
Wang G, Kang MX, Lu WJ, Chen Y, Zhang B
and Wu YL: MACC1: A potential molecule associated with pancreatic
cancer metastasis and chemoresistance. Oncol Lett. 4:783–791.
2012.PubMed/NCBI
|
|
12
|
Shang C, Hong Y, Guo Y, Liu YH and Xue YX:
Influence of the MACC1 gene on sensitivity to chemotherapy in human
U251 glioblastoma cells. Asian Pac J Cancer Prev. 16:195–199. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang R, Shi H, Chen Z, Wu Q, Ren F and
Huang H: Effects of metastasis-associated in colon cancer 1
inhibition by small hairpin RNA on ovarian carcinoma OVCAR-3 cells.
J Exp Clin Cancer Res. 30:832011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen S, Jiao JW, Sun KX, Zong ZH and Zhao
Y: MicroRNA-133b targets glutathione S-transferase π expression to
increase ovarian cancer cell sensitivity to chemotherapy drugs.
Drug Des Devel Ther. 9:5225–5235. 2015.
|
|
15
|
Zhang Z, Xie Z, Sun G, Yang P, Li J, Yang
H, Xiao S, Liu Y, Qiu H, Qin L, et al: Reversing drug resistance of
cisplatin by hsp90 inhibitors in human ovarian cancer cells. Int J
Clin Exp Med. 8:6687–6701. 2015.PubMed/NCBI
|
|
16
|
Li HF, Liu YQ, Shen ZJ, Gan XF, Han JJ,
Liu YY, Li HG and Huang ZQ: Downregulation of MACC1 inhibits
invasion, migration and proliferation, attenuates cisplatin
resistance and induces apoptosis in tongue squamous cell carcinoma.
Oncol Rep. 33:651–660. 2015.
|
|
17
|
Li H, Liao X, Liu Y, Shen Z, Gan X, Li H
and Huang Z: The expression of MACC1 and its role in the
proliferation and apoptosis of salivary adenoid cystic carcinoma. J
Oral Pathol Med. 44:810–817. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Seger R and Krebs EG: The MAPK signaling
cascade. FASEB J. 9:726–735. 1995.PubMed/NCBI
|
|
19
|
Nicosia SV, Bai W, Cheng JQ, Coppola D and
Kruk PA: Oncogenic pathways implicated in ovarian epithelial
cancer. Hematol Oncol Clin North Am. 17:927–943. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jin W, Wu L, Liang K, Liu B, Lu Y and Fan
Z: Roles of the PI-3K and MEK pathways in Ras-mediated
chemoresistance in breast cancer cells. Br J Cancer. 89:185–191.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Montagut C and Settleman J: Targeting the
RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 283:125–134.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Andorfer P and Rotheneder H: Regulation of
the MDR1 promoter by E2F1 and EAPP. FEBS Lett. 587:1504–1509. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen J, Ding Z, Peng Y, Pan F, Li J, Zou
L, Zhang Y and Liang H: HIF-1α inhibition reverses multidrug
resistance in colon cancer cells via downregulation of
MDR1/P-glycoprotein. PLoS One. 9:e988822014. View Article : Google Scholar
|
|
24
|
Wang Q, Wang Z, Chu L, Li X, Kan P, Xin X,
Zhu Y and Yang P: The effects and molecular mechanisms of miR-106a
in multidrug resistance reversal in human glioma U87/DDP and U251/G
cell lines. PLoS One. 10:e01254732015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Januchowski R, Wojtowicz K,
Sujka-Kordowska P, Andrzejewska M and Zabel M: MDR gene expression
analysis of six drug-resistant ovarian cancer cell lines. Biomed
Res Int. 2013:2417632013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang T, Guan M, Jin HY and Lu Y: Reversal
of multidrug resistance by small interfering double-stranded RNAs
in ovarian cancer cells. Gynecol Oncol. 97:501–507. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Thomas S, Quinn BA, Das SK, Dash R, Emdad
L, Dasgupta S, Wang XY, Dent P, Reed JC, Pellecchia M, et al:
Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther
Targets. 17:61–75. 2013. View Article : Google Scholar
|
|
28
|
Babu A, Wang Q, Muralidharan R, Shanker M,
Munshi A and Ramesh R: Chitosan coated polylactic acid
nanoparticle-mediated combinatorial delivery of cisplatin and
siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian
cancer cells. Mol Pharm. 11:2720–2733. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang HL, Lin KY, Juan YC, Kumar KJ, Way
TD, Shen PC, Chen SC and Hseu YC: The anti-cancer activity of
Antrodia camphorata against human ovarian carcinoma (SKOV-3) cells
via modulation of HER-2/neu signaling pathway. J Ethnopharmacol.
148:254–265. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Galluzzi L, Kepp O and Kroemer G:
Caspase-3 and prostaglandins signal for tumor regrowth in cancer
therapy. Oncogene. 31:2805–2808. 2012. View Article : Google Scholar
|
|
31
|
Zhang SD, Shan L, Li W, Li HL and Zhang
WD: Isochamaejasmin induces apoptosis in leukemia cells through
inhibiting Bcl-2 family proteins. Chin J Nat Med. 13:660–666.
2015.PubMed/NCBI
|
